262 related articles for article (PubMed ID: 30526892)
1. The complications of vasculitis and its treatment.
King C; Harper L; Little M
Best Pract Res Clin Rheumatol; 2018 Feb; 32(1):125-136. PubMed ID: 30526892
[TBL] [Abstract][Full Text] [Related]
2. Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis.
Matraiah EH; Olisaka N; Philipos M; Walbaum D; Dospinescu P; Fluck N; Basu N; Kidder D
Clin Rheumatol; 2018 Jul; 37(7):1991-1996. PubMed ID: 29808456
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide.
Nettleton E; Sattui SE; Wallace Z; Putman M
Arthritis Care Res (Hoboken); 2024 Feb; 76(2):288-294. PubMed ID: 37643919
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in ANCA-Associated Vasculitis.
Hassan RI; Gaffo AL
Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
[TBL] [Abstract][Full Text] [Related]
5. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.
van Daalen EE; Rizzo R; Kronbichler A; Wolterbeek R; Bruijn JA; Jayne DR; Bajema IM; Rahmattulla C
Ann Rheum Dis; 2017 Jun; 76(6):1064-1069. PubMed ID: 27899372
[TBL] [Abstract][Full Text] [Related]
6. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
7. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
Jones RB
Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
11. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.
Miloslavsky EM; Niles JL; Wallace ZS; Cortazar FB; Fernandes A; Laliberte K; Stone JH
Semin Arthritis Rheum; 2018 Oct; 48(2):288-292. PubMed ID: 29530330
[TBL] [Abstract][Full Text] [Related]
12. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis.
Thery-Casari C; Euvrard R; Mainbourg S; Durupt S; Reynaud Q; Durieu I; Belot A; Lobbes H; Cabrera N; Lega JC
Autoimmun Rev; 2020 May; 19(5):102505. PubMed ID: 32173512
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment outcomes in pregnant patients with ANCA-associated vasculitides: A systematic review of literature.
Singh P; Dhooria A; Rathi M; Agarwal R; Sharma K; Dhir V; Nada R; Minz R; Suri V; Jain S; Sharma A
Int J Rheum Dis; 2018 Sep; 21(9):1734-1740. PubMed ID: 30345645
[TBL] [Abstract][Full Text] [Related]
15. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
[TBL] [Abstract][Full Text] [Related]
16. Rituximab as maintenance therapy for ANCA associated vasculitis: how, when and why?
Alba MA; Flores-Suárez LF
Reumatol Clin; 2016; 12(1):39-46. PubMed ID: 26255570
[TBL] [Abstract][Full Text] [Related]
17. Management of ANCA associated vasculitis.
Wallace ZS; Miloslavsky EM
BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597
[TBL] [Abstract][Full Text] [Related]
18. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
19. Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.
Haris Á; Dolgos S; Polner K
Int Urol Nephrol; 2017 Jan; 49(1):91-102. PubMed ID: 27671907
[TBL] [Abstract][Full Text] [Related]
20. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
Tesar V; Hruskova Z
Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
